Form 4: CRISPR Therapeutics Director Douglas Treco Granted 13,000 Stock Options

CRISPR Therapeutics AG Director Douglas A. Treco was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

Summary

• Douglas A. Treco, a Director of CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options on June 5, 2025.
• The stock options have an exercise price of $38.57 per common share.
• The options will vest 100% in 12 equal monthly installments, commencing on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the 2026 Annual General Meeting of Shareholders.
• The options are set to expire on June 5, 2035.
• Following this transaction, Mr. Treco beneficially owns 13,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: This is a routine insider transaction filing (Form 4) reporting the grant of stock options to a director, which is a standard compensation event and does not inherently indicate positive or negative sentiment about the company's performance or outlook.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating ongoing engagement and commitment from the board.

Future Outlook

The document details a future vesting schedule for the granted stock options, indicating that the shares will become exercisable in monthly installments over the next year, aligning the director's future compensation with the company's performance.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for directors and executives, as a means of long-term incentive compensation. This aligns the interests of key personnel with the company's growth and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, especially within the biotech sector, where equity-based incentives are prevalent.
• The vesting schedule of 12 equal monthly installments over one year is a common approach to ensure continued commitment and retention, comparable to similar grants observed at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors, though specific terms (e.g., number of options, exercise price) vary based on company size, performance, and individual roles.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with long-term shareholder value creation, as the options' value is tied to the company's stock performance.
• Employees: While not directly impacting general employees, such compensation practices for leadership can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The granted stock options will begin vesting in 12 equal monthly installments starting June 30, 2025.
• The final vesting installment will occur on the earlier of the one-year anniversary of the grant date or the date of the 2026 Annual General Meeting of Shareholders.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Biotechnology